Abeona Therapeutics SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 9, 2026, 6:35 a.m. ETView on SEC.gov
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedAbeona Therapeutics Q3 2026 revenue of $13.5 million misses $14.8 million consensus, though EPS of -$0.08 beats the -$0.17 estimate on non-operating gains
8-KNov. 9, 2026, 6:30 a.m. ETView on SEC.gov
Entry into a material definitive agreement · Completion of acquisition or disposition of assets · Unregistered sales of equity securities · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedAbeona Therapeutics Acquires APT-1011 (ABO-801) for 4,494,383 Shares and Launches $30 Million Private Placement at $3.75 per Share
8-KSept. 15, 2026, 12 p.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
8-KAug. 13, 2026, 7:30 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits